NioCorp Developments is a pre-revenue, US-based miner focused on niobium, scandium, and titanium, rated a Strong Buy after a significant pullback. NB's Elk Creek project is fully permitted, with a 38-year mine life, projected $21.9B gross revenue, and 68% EBITDA margin; production start is 3–4 years away. Current EV of $521M implies a forward EV/EBITDA of 1.29, presenting substantial upside versus sector median multiples, even without rare earth expansion.

A $10,000 Verizon investment in 2015 would be worth just $14,650 today, badly trailing the S&P 500. The same investment made in 2005 grew to $27,400 by 2015, beating the market.

Uber leads the global rideshare and delivery markets. Uber continues to grow its revenue and profits.

Jack in the Box is closing dozens of restaurants as part of a major cost-cutting plan, with 72 locations shuttered so far and more expected in the near future.

Enbridge operates in the most stable segment of the energy sector. The company's reliable cash flows support its attractive yield of 5.9%.

Nvidia licensed Groq's AI inference technology and hired key engineers. Groq will continue to operate independently after the non-exclusive licensing agreement.

Italian regulators ordered Meta on Wednesday to open its WhatsApp chat platform to rival AI chatbots as it and EU authorities pursue a probe that the US tech giant is abusing its dominant market position.

According to the European Automobile Manufacturers' Association (ACEA) November report on EU car registrations, the figure for Tesla Inc.

BYD's registrations in the European Union were up 235.2% in November to 16,158, according to the European Automobile Manufacturers' Association (ACEA).

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a condition affecting millions worldwide with limited effective treatment options.

Intel Corp (NASDAQ:INTC, XETRA:INL) shares fell on Wednesday on a Reuters report that Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) had halted a test of Intel's advanced 18A chipmaking process. According to Reuters, which cited two people familiar with the matter, Nvidia had been evaluating whether its chips could be manufactured using Intel's 18A process, one of Intel's most advanced production technologies.

TTM Technologies (TTMI) is a critical supplier to the AI hardware and defense sectors, with 22% y/y sales growth and record earnings. TTMI's growth is driven by surging AI data center demand and robust aerospace & defense spending, with 80% of Q3 sales tied to these arenas. Despite a 189% YTD stock surge, TTMI trades at a discount on PEG and price/sales metrics relative to sector growth, justifying a Strong Buy rating.

The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.

FS KKR Capital is cutting its base cash dividend by 29.7% to $0.45 per share, with the BDC's yield now the largest versus its large-cap peers. The move comes as NAV per share grew marginally during the third quarter by 6 cents sequentially, against what's been a broader decline since 2023. FSK is trading at a material 34% discount to NAV, with the move to reduce its dividend set to be helpful to drive a recovery and a possible discount narrowing.

JPM is weighing crypto trading for institutions as regulation eases, signaling a shift that could add liquidity and intensify competition.

Some may doubt the Santa Rally this year amid AI overvaluation and inflation woes. Low P/E momentum ETFs -- XMVM, XSVM, PYZ, VAMO -- offer a balanced year-end play.

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this movie before. A company leans hard on a single product, rides momentum while it lasts, then scrambles when conditions change.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef.

Consumer bundle planned for Q2 2026 pairsMudra Link with Rokid Glasses, with live demos at CES 2026 Yokneam Illit, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a collaboration with Rokid – a global pioneer in human-computer interaction and augmented reality, to deliver gesture control for AI and augmented reality (“AR”) glasses that feels natural, fast and consistent in daily use.

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic breast cancer in pivotal phase 3 trials. Company's palazestrant + KISQALI combination achieved a promising 15.5-month mPFS in heavily pretreated patients, addressing endocrine resistance in both ESR1-mutant and wild-type tumors. Key catalysts include OPERA-01 monotherapy data expected in 2H 2026 and OPERA-02 topline results in 2028, with potential NDA filing in 2027 for monotherapy if successful.